Appeal dismissed over capital gains claim on M/s Kappac Pharma Ltd shares.

The court dismissed the appeal concerning the rejection of a long term capital gain claim related to the sale of shares of M/s Kappac Pharma Ltd. The appellant's claim was denied by tax authorities, citing suspicions due to the company's financial status. The appellant's grievances included the denial of the right to cross-examination and alleged errors in the tax authorities' approach. Despite arguments raised, the court found no substantial question of law and upheld the lower authorities' decisions, leading to the dismissal of the appeal.

---

---

Issues:
1. Rejection of long term capital gain claim.
2. Denial of right to cross-examination.
3. Alleged erroneous approach by tax authorities.
4. Suspicions raised due to company's financial status.
5. Dismissal of appeal due to lack of substantial question of law.

Analysis:
1. The judgment deals with the rejection of a long term capital gain claim by the appellant in relation to the sale of shares of M/s Kappac Pharma Ltd. The appellant held the shares for approximately 19 months, with an acquisition price of &8377;12 per share and a sale price of &8377;720 per share. The tax authorities, including the lower appellate authorities, rejected the claim, leading to the appellant's grievance. The appellant argued that a fair opportunity was not granted, citing previous tribunal orders in favor of the same company.

2. The appellant contended that the denial of the right to cross-examination of key individuals whose statements influenced the inquiry and disallowance of the long term capital gain claim was a crucial issue. This denial was highlighted as a violation of procedural fairness and a contributing factor to the adverse findings against the appellant.

3. The judgment addresses the alleged erroneous approach of the tax authorities in handling the appellant's case. The counsel for the appellant argued that the tax authority's approach was erroneous and inconsistent, pointing out discrepancies in the treatment of similar cases involving M/s Kappac Pharma Ltd. The court considered these arguments but found the findings of the authorities to be consistent and concurrent.

4. A significant aspect of the case was the suspicions raised by the Revenue due to the financial status of M/s Kappac Pharma Ltd. The company had meagre resources and reported consistent losses, making the substantial increase in the value of its shares questionable. The court noted that the company was even directed to be delisted from the stock exchange, further raising concerns about the legitimacy of the capital gain claim.

5. Ultimately, the court dismissed the appeal on the grounds that no substantial question of law arose from the case. The court emphasized that the findings were primarily factual, with all levels of authorities consistently rendering adverse decisions against the appellant. Therefore, the appeal was deemed to lack merit for further legal consideration, leading to its dismissal.

---